Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
March 26, 2024
Assignees:
Sanford Burnham Prebys Medical Discovery Institute, Pfizer Inc.
Inventors:
Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.
Type:
Grant
Filed:
October 22, 2019
Date of Patent:
March 19, 2024
Assignees:
Daiichi Sankyo Company Limited, Sanford Burnham Prebys Medical Discovery Institute
Inventors:
Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.
Type:
Grant
Filed:
July 3, 2019
Date of Patent:
March 5, 2024
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Tsuyoshi Nakamura, Mayuko Akiu, Takashi Tsuji, Jun Tanaka, Koji Terayama, Mika Yokoyama, Anthony B. Pinkerton, Edward Hampton Sessions
Abstract: Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
Type:
Grant
Filed:
July 29, 2021
Date of Patent:
February 27, 2024
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Nicholas David Peter Cosford, Mitchell Dennis Vamos
Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.
Type:
Grant
Filed:
August 12, 2019
Date of Patent:
February 20, 2024
Assignees:
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Otto Phanstiel, IV, Holly Moots, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla
Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
February 6, 2024
Assignees:
VIRGINIA COMMONWEALTH UNIVERSITY, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Paul B. Fisher, Maurizio Pellecchia, Swadesh K. Das, Timothy P. Kegelman, Bainan Wu, Surya K. De, Jun Wei, Mitchell E. Menezes, Luni Emdad
Abstract: Disclosed herein are methods of diagnosing and treating MYC-driven cancers by detecting a PVT1 splice variant in a biological sample from a subject.
Type:
Grant
Filed:
May 8, 2019
Date of Patent:
January 9, 2024
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Abstract: Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.
Type:
Grant
Filed:
May 22, 2020
Date of Patent:
December 12, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Abstract: This disclosure relates to cardiogenic mesoderm formation regulators and methods of use thereof, e.g., generating a multipotent cardiovascular progenitor cell by overexpressing Id1, Id2, Id3, Id4, Evx1, and/or Grrp1 in a stem cell.
Type:
Grant
Filed:
August 13, 2018
Date of Patent:
November 21, 2023
Assignee:
Sanford Burnham Prebys Medical Discovery Institute
Inventors:
Alexandre Romain Colas, Mark Mercola, Wesley Lawrence McKeithan, Michael Shenghan Yu
Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
Type:
Grant
Filed:
July 27, 2022
Date of Patent:
November 7, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Stephen Gardell, Anthony B. Pinkerton, Eduard Sergienko, Hampton Sessions
Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
Type:
Grant
Filed:
June 8, 2021
Date of Patent:
August 22, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
Abstract: Methods are disclosed for treating periodontal disease, peri-implantitis, or to preserve a tooth socket in a subject. These methods include selecting a subject with periodontal disease, peri-implantitis, or in need of tooth socket preservation; and locally administering into the periodontium of the subject a therapeutically effective amount of a tissue-nonspecific alkaline phosphatase (TNAP) polypeptide, or a nucleic acid molecule encoding the recombinant TNAP polypeptide. Methods are also disclosed for i) promoting alveolar bone regeneration in the subject; ii) increasing attachment of a periodontal ligament to a root surface of a tooth in the subject; iii) increasing cementum formation; and/or iv) increasing mineralization in a tooth in the subject. Pharmaceutical compositions are also disclosed that are of use in these methods.
Type:
Application
Filed:
December 31, 2020
Publication date:
June 29, 2023
Applicants:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN, OHIO STATE INNOVATION FOUNDATION, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITY
Inventors:
Martha J. Somerman, Nadine Laure Samara, Atsuhiro Nagasaki, Demetrios T. Braddock, Brian Lee Foster, Jose Luis Millan
Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Type:
Grant
Filed:
May 7, 2020
Date of Patent:
June 13, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
Abstract: The present invention is based on the seminal discovery of a panel of targeting peptides and antibodies that can recognize AD brains at different stages of the disease, starting from early to advanced stage. The peptide probes described here are unique in the field and can be expected to advance understanding on early neurodegenerative changes associated with AD and improve the therapeutic outcomes by early detection and intervention in AD. Further, the invention provides antibodies that can be used to treat AD.
Type:
Grant
Filed:
November 16, 2017
Date of Patent:
February 7, 2023
Assignee:
Sanford Burnham Prebys Medical Discovery Institute
Inventors:
Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
Abstract: Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
February 7, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Tambet Teesalu, Pablo Scodeller, Erkki Ruoslahti
Abstract: Disclosed herein are methods of inhibiting nuclear pore complex assembly and inducing nuclear pore complex disassembly. Methods to screen for agents that inhibit nuclear pore assembly or induce nuclear pore complex disassembly are also disclosed.
Type:
Grant
Filed:
July 10, 2018
Date of Patent:
January 31, 2023
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).
Type:
Grant
Filed:
June 1, 2020
Date of Patent:
November 29, 2022
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
Abstract: Compositions are disclosed which include a CAQK peptide linked or conjugated to a cargo composition, where the peptide selectively homes the composition to a site of nervous system injury in a subject.
Type:
Grant
Filed:
April 27, 2020
Date of Patent:
October 4, 2022
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
Type:
Grant
Filed:
January 9, 2018
Date of Patent:
September 27, 2022
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Stephen Gardell, Anthony B. Pinkerton, Eduard Sergienko, Hampton Sessions
Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
Type:
Grant
Filed:
March 12, 2020
Date of Patent:
September 20, 2022
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler, John Howard Hutchinson, Reto Andreas Gadient